Our Technology
Our Technology
Our Platform
- Virometix’ platform is designed for tailor-made vaccine candidates.
- Virometix develops structure-based, fully synthetic nanoparticle vaccines designed to elicit targeted, robust, and durable immune responses. Its proprietary Synthetic Virus-Like Particle (SVLP) platform employs conformational synthetic peptide mimetics displayed on self-assembling lipopeptidic nanoparticles that include built-in adjuvant elements, including T-helper epitopes and Toll-like receptor (TLR) ligands—eliminating dependence on biological components and simplifying manufacturing.
Intellectual Property
Our growing patent portfolio includes umbrella patents granted for the SVLP platform. In addition, Virometix has established exclusive license and IPR agreements for patent rights owned by the University of Zurich and other scientific institutions. We have also generated proprietary know-how and expertise for designing, upscaling, and optimizing SVLPs and synthetic antigens. Virometix maximizes the protection of its technology, products, and interests in all relevant markets.